These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 603318)

  • 1. Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug.
    Kesteloot H; Stroobandt R
    Arch Int Pharmacodyn Ther; 1977 Dec; 230(2):225-34. PubMed ID: 603318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic effect of lorcainide during chronic treatment.
    Meinertz T; Kasper W; Kersting F; Bechtold H; Just H; Jähnchen E
    Arzneimittelforschung; 1980; 30(9):1593-5. PubMed ID: 7193031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug.
    Kesteloot H; Stroobandt R
    Eur J Clin Pharmacol; 1979 Nov; 16(5):323-6. PubMed ID: 93050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of lorcainide, a new anti-arrhythmic agent.
    Lloyd EA; Workman LJ; Commerford PJ; Mabin TA
    S Afr Med J; 1981 Dec; 60(24):929-31. PubMed ID: 7302777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorcainide. II. Plasma concentration-effect relationship.
    Meinertz T; Kasper W; Kersting F; Just H; Bechtold H; Jähnchen E
    Clin Pharmacol Ther; 1979 Aug; 26(2):196-204. PubMed ID: 455888
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases].
    Coumel P; Leclercq JF; Assayag P; Maisonblanche P; Cauchemez B
    Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1370-82. PubMed ID: 6439161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary clinical and experimental data on a new anti-arrhythmic drug: lorcainide].
    Pretolani E; Battistini G; Iosa G; Mambelli M; Pigini G; Zoli I
    Minerva Med; 1980 Apr; 71(13):975-80. PubMed ID: 7375011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcainide in the prophylaxis of ventricular arrhythmias in acute myocardial infarction.
    Leinonen H; Heikkilä J; Sundberg S; Gordin A
    Ann Clin Res; 1984; 16(1):18-22. PubMed ID: 6378045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorcainide -- an anti-arrhythmic agent for ventricular arrhythmias.
    Myburgh DP; Goldman AP; Schamroth JM
    S Afr Med J; 1980 Feb; 57(7):236-9. PubMed ID: 7404136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of a new anti-arrhythmic drug: propafenon. Short and long-term results].
    Ruipércz Abizanda JA; Campos Peris JV; García García J; Jaen Armand E; Ruiz Ros JA; Salas Nieto J; Rodríguez Ruiz P; Marco Quiles J; Martínez Jérez M; Pico Aracil F
    Arch Inst Cardiol Mex; 1981; 51(4):371-6. PubMed ID: 7337481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce; Brogden RN
    Drugs; 1984 Apr; 27(4):279-300. PubMed ID: 6373222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    Echt DS; Mitchell LB; Kates RE; Winkle RA
    Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent.
    Cocco G; Strozzi C
    Eur J Clin Pharmacol; 1978 Nov; 14(2):105-9. PubMed ID: 363430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-arrhythmic effect of dazolicin. Clinical-pharmacological research].
    Beck OA; Spielmann H; Witt E; Oeff M; Liddard C; Hochrein H
    Arzneimittelforschung; 1980; 30(12):2172-81. PubMed ID: 7194081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorcainide. I. Saturable presystemic elimination.
    Jähnchen E; Bechtold H; Kasper W; Kersting F; Just H; Heykants J; Meinertz T
    Clin Pharmacol Ther; 1979 Aug; 26(2):187-95. PubMed ID: 455887
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lorcainide in stable ventricular extrasystole. A double-blind study with 48-hour continuous ECG recording].
    Buss J; Stegaru B; Geiger S; Gores D; Heene DL
    Dtsch Med Wochenschr; 1984 Nov; 109(48):1829-32. PubMed ID: 6209080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.
    Carmeliet E; Janssen PA; Marsboom R; Van Nueten JM; Xhonneux R
    Arch Int Pharmacodyn Ther; 1978 Jan; 231(1):104-30. PubMed ID: 637616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
    Stroobandt R; Kesteloot H
    Acta Cardiol; 1985; 40(6):637-48. PubMed ID: 3879420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistant ventricular arrhythmias treated with lorcainide, a new antiarrhythmic drug.
    Somani P; di Giorgi S
    Chest; 1980 Oct; 78(4):658-60. PubMed ID: 7418495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.